An interventional study of Medium Supplemented with Latrunculin B in Infertility, sponsored by Ibn Sina Hospital. Completed at 3 sites in Egypt. Open to female participants aged 18 Years to 42 Years. Per ClinicalTrials.gov, last updated 2019-05-07.
Sponsored by Ibn Sina Hospital · Not applicable, Interventional, and Other
Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Latrunculin B serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Latrunculin B during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes,
2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.
This study's enrollment of 300 is above the median of 120 across 1,698 interventional studies indexed under Infertility.
Browse Infertility studies →Ibn Sina Hospital is the lead sponsor of 28 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
-
Other: Medium Supplemented with Latrunculin B
A medium with in-house supplementation of Latrunculin B to decrease oocyte degeneration after ICSI and improve the survival rate
oocyte survival rate after ICSI
Time frame: 6 days of culture
Fertilisation rate
Time frame: 6 days of culture
Rates of blastocyst formation and quality
Number of formed and high-quality blastocysts per fertilized oocytes
Time frame: 6 days of culture
Clinical pregnancy rate
Time frame: three months
Implantation rate
Time frame: 7 weeks
Ongoing pregnancy rate
Time frame: 12 weeks
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ibn Sina Hospital